Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Debuts include DexCom’s G4 Platinum continuous glucose monitor, OraSure’s OraQuick in-home HIV test and St. Jude’s MediGuide 3D navigation system for cardiovascular procedures.

You may also be interested in...

People In Brief

JenaValve, Predictive Biosciences, DexCom among firms with personnel news.

St. Jude Confident In 2013 Growth Plan Despite Market Challenges

Anticipated growth drivers include the firm’s MediGuide catheter tracking system, EnligHTN multi-electrode renal denervation system and Portico transcatheter aortic valve, aided by a return to stability of the cardiac rhythm management market by the first half of 2013.

OraSure Preps October Launch Of First-Ever In-Home HIV Test

Firm gains PMA approval for OraQuick July 3, making it the first available HIV test that can be performed entirely in the home by untrained users.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts